Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 13 June 2013 | By Alexander Gaffney, RAC,
In a landmark decision, the Supreme Court has decided in favor of the Association for Molecular Pathology in its case against Myriad Genetics, ruling that naturally occurring DNA is not patentable, while synthetic DNA is.
The case, heard in April 2013, concerned patents held on two genes, BRCA 1 and BRCA2, which are closely linked to a woman's risk of breast and ovarian cancer. Myriad Genetics, a biotechnology company, owned the patent rights to the use of the two genes, which it used to make a considerable sum of money licensing the use of diagnostic tools used to inform patient treatment.
But the Association for Molecular Pathology and other groups filed a lawsuit again the company - the same the Supreme Court ruled on today - concerning a difficult question: Is the genetic code of the human body a patentable entity?
Myriad had argued that it was, and that without sufficient protections for intellectual property, incentives would not exist to permit investment in the discovery of genes linked to diseases. Meanwhile AMP and others argued that Myriad had in effect patented parts of the human body itself - "products of nature" - to which it had no claim, interrupting basic science.
In a widely anticipated decision issued on 13 June 2013, the Supreme Court decided in favor of AMP, holding that "a naturally occurring deoxyribonucleic acid (DNA) segment is a product of nature and not patent eligible merely because it has been isolated."
"Myriad's DNA claim falls within the law of nature exception," the court wrote. "Myriad's principal contribution was uncovering the precise location and genetic sequence of the BRCA1 and BRCA2 genes," but this failed a patent eligible standard since it lacked "markedly different characteristics from any found in nature."
So while the court held that Myriad had found an important and useful gene, a "groundbreaking, innovative or even brilliant discovery does not by itself satisfy [patent requirements]," it said. In addition, though the court recognized Myriad's considerable effort in discovering the BRCA genes, it noted that "extensive effort alone is insufficient" to hold a patent as valid.
However, in a nod to Myriad's argument, the Supreme Court also held that composite DNA (cDNA) - a synthetic isolate - is patent eligible "because it is not naturally occurring."
"cDNA does not present the same obstacles to patentability as naturally occurring, isolated DNA segments," the court explained. "Its creation results in an exons-only molecule, which is not naturally occurring. Its order of the exons may be dictated by nature, but the lab technician unquestionably creates something new when introns are removed from a DNA sequence to make cDNA."
The court's decision, landmark in its effect, is also remarkable in one other respect: The opinion was joined by all nine justices, with only Justice Antonin Scalia filing an opinion concurring in part with the judgment. The overwhelming support makes it unlikely that the case will be revisited in the future.
The case has already won strong support from Francis Collins, the director of the National Institutes of Health (NIH), who immediately sent out a message on Twitter exclaiming: "Woo Hoo!!!"
SCOTUS Decision -- PDF
Tags: Myriad, SCOTUS, AMP, Supreme Court
Regulatory Focus newsletters
All the biggest regulatory news and happenings.